Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cynanchum atratum, known in traditional Chinese medicine as Baiwei, is a perennial herb from the Apocynaceae family that has been utilized for over 2,000 years for its antipyretic, anti-inflammatory, and diuretic properties. The medicinal portion consists of the dried root and rhizome, which contain a diverse array of bioactive C21 steroidal saponins. Traditionally, it is indicated for the treatment of yin-deficiency fever, postpartum fever, urinary tract infections, and inflammatory skin conditions such as atopic dermatitis. Modern pharmacological research has explored its potential in metabolic health, specifically for non-alcoholic fatty liver disease (NAFLD) through the activation of the AMPK pathway, and in dermatology for its anti-melanogenic effects mediated via the cAMP/MITF signaling pathway. It is typically administered as a botanical extract rather than a purified pharmaceutical compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cynanchum atratum.